[Breast cancer: radiotherapy and estrogen signaling]

Bull Cancer. 2014 Jul-Aug;101(7-8):714-7. doi: 10.1684/bdc.2014.1954.
[Article in French]

Abstract

Hormone receptors are expressed in more than 75% of breast cancer. Therefore, two prescription modalities of endocrine therapy could be proposed: either sequential or concomitant to breast cancer irradiation. If combined to radiotherapy, is endocrine therapy a radiosensitizer? Does endocrine therapy enhance the risk factor of radio-induced toxicity? Here, we will distinguish the interaction of ionizing radiation combined with therapies targeting oestrogen receptor (REα) from the interaction of ionizing radiation with oestrogen. This review aims at making clear all these items.

Keywords: adjuvant; breast cancer; concomitant; endocrine therapy; radiotherapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / therapy*
  • Chemoradiotherapy / methods*
  • Estradiol / analogs & derivatives
  • Estradiol / therapeutic use
  • Estrogens / metabolism*
  • Female
  • Fulvestrant
  • Humans
  • Molecular Targeted Therapy / methods
  • Radiation Pneumonitis / etiology
  • Randomized Controlled Trials as Topic
  • Receptors, Estrogen / metabolism*
  • Signal Transduction
  • Tamoxifen / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Estrogens
  • Receptors, Estrogen
  • Tamoxifen
  • Fulvestrant
  • Estradiol